Veterinary Monoclonal Antibodies Market
Veterinary Monoclonal Antibodies Market Size, Share, Competitive Landscape and Trend Analysis Report by Animal Type, Product Type, Therapy Area, Route of Administration and End User. Global Opportunity and Industry Forecast (2025-2032)
Report ID:
1180
Industry:
Healthcare
Published on:
March 2026
Veterinary Monoclonal Antibodies Market Summary:
Global Veterinary Monoclonal Antibodies Market size was valued at USD 1.70 Billion in 2025 and is Expected grow to USD 3.88 Billion by 2032, growing at a CAGR of 12.50% during the forecast period (2025-2032).
Veterinary Monoclonal Antibodies Trends and Analytical Insights -
North America Veterinary Monoclonal Antibodies Market was the largest revenue generating region market in year 2025, with market share accounted for 46.54%.
In 2025, By Animal Type, Dogs dominated the Veterinary Monoclonal Antibodies Market, accounted for 48.11 % market shares.
Leading Key players for Dairy Herd Management Market in 2025 was Zoetis Inc., Elanco Animal Health Incorporated and Merck & Co., Inc.
Veterinary Monoclonal Antibodies Market Size & Forecast
Market Size 2025: USD 1.70 Billion
Projected Market Size 2032: USD 3.88 Billion
CAGR (2025-2032): 12.50%
North America: Dominating market in 2025
Veterinary Monoclonal Antibodies Market Overview
The veterinary monoclonal antibodies industry was focusing on developing, producing, and distributing monoclonal antibodies to treat animals. Monoclonal antibodies were being used as biopharmaceutical drugs to target specific molecules (i.e., antigens) found in animal patients. Veterinary monoclonal antibodies were being primarily used for the treatment of chronic conditions (e.g., allergic dermatitis, osteoarthritis, inflammatory conditions) or for disease prevention. Veterinary monoclonal antibodies were providing a more targeted therapeutic effect than conventional pharmaceuticals and were also having a lower risk of adverse reactions than conventional drugs. Veterinary prescribed biologics were being increasingly adopted as veterinary technology was advancing to more targeted treatments. By 2024, there were being approximately 470 million companion animals worldwide, and about 6.5% increase in the number of total veterinary visits per year for the veterinary medical sectors was continuing to be seen throughout most of the developed veterinary systems.
Veterinary Monoclonal Antibodies was a growing market because veterinary biotech companies were developing innovative biologics and new technologies to engineer monoclonal antibodies; also, pharmaceutical companies and research institutions were investing more into animal-specific therapeutic antibodies. The number of veterinary biologics approved between 2020-2025 was consistently rising as there were over 15 different antibody-based veterinary therapies being studied in their respective clinical pipelines. The rise in ownership of pets was continuing to grow among urban households, with nearly 2020-2025 of households in developed countries owning at least 1 pet as of 2023. Veterinary hospitals and specialty clinics were also beginning to use monoclonal antibody therapies to provide long-term management of diseases for canines and felines. Together, these positive trends were continuing to facilitate considerable amounts of research and commercialization within the global animal health industry.
Veterinary Monoclonal Antibodies Market Dynamics
The growth in pet ownership and increasing awareness of advanced therapies for treating animals was driving the expansion of the Veterinary monoclonal antibodies market. Pets were being treated more like family members, thus resulting in an ever-increasing amount of money being spent on their health needs. The number of veterinary visits in 2023 was being expected to be almost 8% higher than the number of visits recorded during 2021. Practitioners were increasingly using targeted biological therapies, which were providing longer-lasting treatments with fewer side effects than standard medications. Furthermore, the use of monoclonal antibodies was decreasing the frequency of drug administration required; this was leading to improved compliance with prescribed medications by pet owners compared to other types of medications. Research institutions involved in pharmaceuticals were working on creating monoclonal antibodies to address nerve growth factors and inflammatory cytokines caused by disease in animals. The development of more effective treatments was aiding in helping pets suffering from chronic skin and joint issues.
Veterinary monoclonal antibody (mAb) manufacturing was being held back by manufacturing complexities, and biological product regulatory approvals/authorities. MAb use in veterinary medicine was requiring specialized biomanufacturing facilities (biotech labs) and high-precision purification processes, which were leading to increased costs for manufacturers. For example, approval timeframes for veterinary biologics were requiring extensive safety and effectiveness data prior to being made available for commercial sales. Nonetheless, there were a number of emerging opportunities for the vaccine and biologic industries. Veterinary biotech companies were investing in antibody engineering and recombinant protein technology to improve specificity of treatment. More than 20 veterinary biologic research programs were being initiated worldwide (across all species) from 2022 through 2024. Growth of livestock health monitoring and disease management programs was also creating additional sales opportunities for monoclonal antibody therapies in cattle (dairy and beef) and other farm animals.
Technology development and product launches by veterinary drug manufacturers were coming quickly for future advances in veterinary monoclonal antibodies. Many companies were developing monoclonal antibodies to treat autoimmune dermatoses and chronic pain in companion animals. In 2024, numerous veterinary biologics trials were being performed on immune-mediated diseases and inflammatory conditions in cats and dogs. Strategic collaborations between biotech companies and veterinary research institutions were increasing as well. Veterinary diagnostic labs were using biologic therapy monitoring programs to help veterinarians provide individualized treatments to their patients. The number of veterinary specialty clinics that were providing advanced biologic treatments was increasing in major markets for animal health. All of these developments were indicating significant innovation activity and were facilitating broader acceptance of veterinary monoclonal antibody therapeutics.
Veterinary Monoclonal Antibodies Market Segment Analysis
The Veterinary Monoclonal Antibodies Market is segmented into By Animal Type, Product Type, Therapy Area, Route of Administration and End User.
By Animal Type,
Based on the animal type, the market is segmented into dogs (canine), cats (feline), livestock animals, and other companion animals. In 2025, the dogs segment dominated the Veterinary Monoclonal Antibodies Market, accounting for 48.11 % of the total market share. Monoclonal antibody treatments in dogs were representing the greatest number of patients being treated with monoclonal antibody therapies among all patients (including human patients) and were being commonly used to manage allergy-related dermatitis and osteoarthritis pain in the canine species. According to data that was being collected during 2022 - 2024, approximately 12 - 15% of owned dogs in these countries were suffering from chronic allergic dermatitis that was requiring medical treatment. Monoclonal antibody therapies were providing longer periods without itching than previously used treatments (with some patients experiencing up to 2022 - 2024 weeks of relief from a single injection). In addition, the use of canine medical treatment was increasing through pet insurance coverage that was expanding in many of the western world's established veterinary healthcare systems. Therefore, pet pharmaceutical manufacturers were developing canine-specific biologic (monoclonal antibody) programs within their development pipelines, which was further strengthening this product segment and continuing to dominate the veterinary monoclonal antibody marketplace.
By Product Type,
Based on the product type, the market is segmented into Anti-IL-31 Monoclonal Antibodies, Anti-NGF Monoclonal Antibodies, Immune-Modulating mAbs, and Other Targeted mAbs. In 2025, the Anti-IL-31 Monoclonal Antibodies segment dominated the Veterinary Monoclonal Antibodies Market, accounting for 41.32% of the total market share. In recent years, many veterinarians were turning to anti-interleukin 31 (IL-31)) monoclonal antibodies when they were addressing allergies or itchy skin problems in companion animals. They were becoming an increasingly popular choice for long-term management of chronic skin disease in dogs. Clinical evaluations that were being conducted between -31) and 2024 were suggesting that anti-IL-31 medications were reducing itching symptoms by approximately 70% after just one round of treatment. Many pet owners were preferring medication based on a biologic injection rather than continuing to use corticosteroids over long periods because they were experiencing a lower likelihood of side effects with this treatment. Additionally, several veterinary pharmaceutical manufacturers were focusing their research and development efforts on therapeutic pipeline development, specifically involving development of medications that were targeting IL-31), which was resulting in an increase in the number of available biologically based treatments in veterinary clinics. All of these factors were serving to solidify the ongoing dominance of anti-IL-31) medications within the Veterinary Monoclonal Antibodies Market.
Veterinary Monoclonal Antibodies Market Region Analysis
In 2025, North America region dominated the Veterinary Monoclonal Antibodies Market with a share of 44% of the global market. The Veterinary Monoclonal Antibodies Market was being dominated by the North American region, which was having a highly developed veterinary healthcare system and was experiencing an increase in the spending on pet healthcare every year. In 2024, veterinary services expenditures in the U.S. were exceeding $35 million due to demand for advanced animal pharmaceuticals. Veterinary hospitals and veterinary specialty clinics were widely utilizing biologics to treat animals with dermatology and orthopaedic disorders. In 2024 million pets were being covered by pet insurance, leading to a more affordable option of using advanced veterinary medicines for pets. Biotechnology companies in both the U.S. and Canada were continuing to develop and were investing large amounts of capital into veterinary biologic product research and development programs. The well-constructed veterinary infrastructure, advanced clinical research capabilities, and the high level of knowledge regarding animal healthcare were contributing to North America's continued dominance in the Veterinary Monoclonal Antibodies Market.
Veterinary Monoclonal Antibodies Market Competitive Analysis
Within the Veterinary Monoclonal Antibodies Marketplace, large multinational animal health manufacturers were investing substantial resources into innovative biologics offerings and veterinary biotechnology research. The leading manufacturers were making investments into antibody discovery platforms, were performing veterinary clinical trials, and were establishing strategic alliances with research institutions to develop monoclonal antibody products targeting skin conditions, pain management, and immune-mediated diseases in animals. Via acquisitions and collaborating on research initiatives, animal health pharmaceutical companies were growing their product pipelines, while also were expanding their manufacturing capacity for biologics and biologically-based products to meet increased veterinary demand. Ongoing research into antibody engineering and veterinary immunology was allowing companies to develop future developments of biologically-based therapy to enhance their overall competitiveness in the veterinary monoclonal antibody marketplace.
Veterinary Monoclonal Antibodies Market Scope
Key Players –
Elanco Animal Health Incorporated
Boehringer Ingelheim Animal Health
Vetoquinol S.A.
Dechra Pharmaceuticals PLC
Phibro Animal Health Corporation
Biogenesis Bago S.A.
Vetigenics Inc.
Animab AB
VETmAb BIO
WuXi Biologics
Bio‑Rad Laboratories, Inc.
SouthernBiotech
Frequently Ask Questions –
1) What is the Veterinary Monoclonal Antibodies Market?
Ans - The Veterinary Monoclonal Antibodies Market was representing the industry focused on biologic antibody therapies developed for animal diseases and immune-related conditions.
2) What factors were supporting the Veterinary Monoclonal Antibodies Market growth?
Ans - Increasing pet ownership, rising veterinary healthcare spending, and growing adoption of targeted biologic treatments were supporting the Veterinary Monoclonal Antibodies Market.
3) Which animal segment dominated the Veterinary Monoclonal Antibodies Market?
Ans - Dogs were dominating the Veterinary Monoclonal Antibodies Market as dermatological and orthopedic conditions were frequently treated in canine populations.
4) What types of products were widely used in the Veterinary Monoclonal Antibodies Market?
Ans - Anti-IL-31 monoclonal antibodies and Anti-NGF monoclonal antibodies were widely used therapies in the Veterinary Monoclonal Antibodies Market.
5) Which region was leading the Veterinary Monoclonal Antibodies Market?
Ans - North America was leading the Veterinary Monoclonal Antibodies Market with strong veterinary infrastructure and advanced animal healthcare systems.